Johnson & Johnson(JNJ) - Stock detail

Johnson & Johnson

US
JNJ
Johnson & Johnson(Listing date: 09/25/1944)

Johnson & Johnson was incorporated in New Jersey in 1887. Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacturing and sale of various products in the healthcare field. Johnson & Johnson is a holding company, with its operating companies located in nearly all countries around the world. The company's primary focus is on products related to human health and well-being. The company is divided into two business segments: Innovative Medicine and MedTech.

AI Trading DecisionBuy
Generated at:2026-04-17 17:46:32
Analysis based on company reports, analyst research (Barclays, Morgan Stanley), and technical indicators. Data includes Q1 2026 financial results (sales, net income), dividend history, price targets, and current market data as of the report generation date. Technical analysis includes RSI and Bollinger Band readings.
Summary

Johnson & Johnson (JNJ) presents a BUY opportunity based on strong fundamentals outweighing short-term technical concerns. The primary 3-month target price is $252.00, representing a +7.6% increase from the current price of $234.18. A stop-loss price is set at $229.90, just below major $230 support. The confidence level in this recommendation is 0.75, and the risk score is assessed at 0.45, indicating a moderate level of risk.

Operation strategy
  • Recommended Holding Period: 3-6 months for tactical trade, longer for dividend growth.
  • Entry Strategy: Scale into position - 50% at current levels, 50% on close above $238 or pullback to $230.
  • Exit Strategy: Take partial profits at $248, reevaluate at $252.

Core Support

Reasoning summary
  • Strong Q1 2026 Execution Validates Growth Strategy: Q1 sales of $24.06B and net income of $5.24B demonstrate above-peer top-line growth; company projects $100B revenue for 2026; 64th consecutive dividend increase signals robust cash flow.
  • Analyst Conviction Supports Upside: Barclays raised price target to $255 based on Strong Pharma Momentum; Morgan Stanley notes stock may still have room to run; fundamentals report indicates current price is below fair value range.
  • Pipeline Offsets Stelara Concerns: Stelara biosimilar threat is well-telegraphed and being actively managed; new growth drivers and MedTech segment showing strength; double-digit growth target by 2030 provides long-term visibility.
  • Technical Oversold Condition Creates Entry Opportunity: Current RSI(6) at 27.27 indicates short-term oversold condition; price near lower Bollinger Band suggests volatility-adjusted oversold state; 92% estimated holders underwater creates potential for short covering on positive news.
  • Defensive Characteristics Provide Downside Protection: Dividend King status with 64-year growth record attracts stable capital; healthcare sector defensive nature provides resilience; current yield of ~2.3% provides income cushion.
  • Primary Risk: Failure to execute on post-Stelara growth strategy.
  • Technical Risk: Overhead supply at $238-$242 may cap initial rebound.
  • Market Risk: Broader market correction could pressure all equities.
  • Valuation Risk: P/E of 26.85 requires continued earnings growth.